Skip navigation

CALBIO2013

CALBIO2013 is a statewide conference that has a global focus on bringing together the life sciences sector in California and targeting delegates from around the world - nearly 1,100 company executives, innovators, government representatives, medical research and disease foundation representatives, university transfer officers, philanthropists and investors will attend.

. Biotechnology and pharmaceutical companies from California and globally, interested in exchange of best business and operational practices as well as non-profit/for-profit collaborations necessary for the successful commercialization of new therapies

. Investors from across the United States and abroad seeking to invest their funds in a targeted, efficient, and effective manner

. Medical research foundations and institutes that are outcomes-driven and strategic in their allocation of resources

. Thought leaders and innovators with diverse experiences and expertise all committed to expediting the research and development process

. University transfer offices focused on facilitating the transfer of university-developed research results to industry for commercial development purposes

An improved feature this year - Business Partnering:

There is no substitute for a face-to-face meeting. Business Partnering at CALBIO2013 will help attendees to maximize their time and meeting opportunities at the Conference. Once registered for the conference, attendees will be given access to an online dating tool that will allow you to perform quick and advanced searches of companies, products and individual conference attendees to best identify potential business partners. 

Axol Bioscience Opens US Office

Axol, the rapidly growing specialist in human cell culture, is delighted to announce it has opened a new operational hub in the US. The site which opened for business in Massachusetts on Friday 21st September will help support Axol’s customer base in the United States and Canada. More »
21 September 2018

Domainex Appoints Dr Trevor Perrior as Chief Executive Officer

Domainex Ltd is pleased to announce the appointment of Dr Trevor Perrior as Chief Executive Officer, effective from 1st October 2018. More »
20 September 2018

AMSBIO: Circulating Tumor DNA Reference Standards

AMSBIO announce the launch of a new range of circulating tumor DNA (ctDNA) Reference Standards for cancer disease management research. More »
19 September 2018

Novel Deep Learning Drug Discovery Platform gets £1 Million Innovation Boost

Optibrium, Intellegens and Medicines Discovery Catapult awarded funding to apply machine learning in drug discovery More »
19 September 2018

Cambridge Networks: Peer Learning will Benefit New Managers

Are you new to a management role or about to take on management responsibilities? Boost your confidence through collaboration with like-minded people in Cambridge Network's New Managers peer learning group - the newest cohort begins on Wednesday 3rd October. More »
18 September 2018

One Nucleus Strikes Collaboration Deal with Science Exchange To Support Members’ Outsourced R&D Strategies

More »
17 September 2018

Sphere Fluidics introduces new Cyto-Mine Studio Software Suite

Cambridge, UK, 17 September 2018: Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, today introduced Cyto-Mine® Studio Software Suite, an updated software for its innovative Cyto-Mine Single Cell Analysis System. The software works alongside industry-standard robotic platforms and corporate databases to improve antibody discovery and cell line development workflows. More »
17 September 2018

Discovery Follows Successful Collaboration between Selcia, Cypralis and Gilead Sciences

A paper entitled ‘Discovery of a Potent and Orally Bioavailable Cyclophilin Inhibitor Derived from the Sanglifehrin Macrocycle’ by authors from Selcia, Cypralis and Gilead has been selected as a featured article by the editors of The Journal of Medicinal Chemistry. More »
17 September 2018

Owlstone Medical Appoints Dr Andy Richards CBE to Board of Directors

Cambridge, UK, September 14 2018: Owlstone Medical Ltd (or the “Company”), a global diagnostics company developing a breathalyzer for early disease detection and precision medicine, announced today the addition of Dr Andy Richards CBE to its Board as a Non-Executive Director. More »
17 September 2018

Inivata Achieves Major Milestone with Draft Medicare Local Coverage Determination (LCD)

Draft Coverage Supports the Use of InVisionFirst-Lung for Aiding in the Management of Patients with Advanced Non-Small-Cell Lung Cancer More »
13 September 2018

<< Previous   Page 1 of 47   Next >>